Keystone Resort Floorplan
Registered Attendees
Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:
- Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting
(You can edit your own abstract from My Account page as well)
NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.
- Full participant list, including joint meeting participants
- Printable Invoices and Invitation Letters
- Scholarship Information
- Lodging Information
Login to My Account page
This meeting took place in 2014
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
Fibrosis: From Bench to Bedside (C4)
Organizer(s) Jeremy S. Duffield, Steven R. Ledbetter and John P. Iredale
March 23—28, 2014
Keystone Resort • Keystone, CO USA
Discounted Abstract Deadline: Nov 20, 2013
Abstract Deadline: Dec 18, 2013
Scholarship Deadline: Nov 20, 2013
Discounted Registration Deadline: Jan 21, 2014
Sponsored by Gilead Sciences, Inc., InterMune, Inc., MedImmune, Shire Human Genetic Therapies and Takeda Pharmaceutical Company Limited
Summary of Meeting:
Fibrosis of all the internal organs is increasingly recognized as a deleterious and ominous consequence of, normal aging, repetitive subclinical tissue injury or severe persistent tissue injury. Fibrosis is increasingly seen as the next broad-ranging target for therapeutics after Cancer, and there is now a rush to first-in-class therapeutics. The primary cell that lays down fibrotic tissue is the myofibroblast. Until very recently, the biology of myofibroblasts is relatively undeveloped due to a lack of definitive markers, and lack of clear ontogeny. This meeting: 1) Brings together biotech, pharma and academia in a seamless meeting. 2) Focuses on fibrosis as an abnormal wound healing or tissue repair response identifying aberrant developmental pathways, and progenitor cell responses. c) Has a broad focus on basic biology of myofibroblasts, their progenitors, progenitor ontogeny, and their interaction with the immune system in disease. d) Focuses on fibrosis as a normal part of aging and the epigenetics involved in maintaining myofibroblasts in an activated state. e) Includes a full session on biomarkers; among the major blocks to progress is the lack of biomarkers. f) Feature formal presentations from biotech/pharma on the most promising new therapeutics in development or clinical trial. All of these highlighted areas are underdeveloped and are rapidly changing. The Keystone Symposia Fibrosis meeting is intended to be the premier international meeting for anyone with an interest in this disease process. The meeting brings together academics from a broad range of interest areas, including cancer, vascular biology, stem cell biology and tissue regeneration, as well as those with organ specific-interests.
View Scholarships/Awards
Fibrosis of all the internal organs is increasingly recognized as a deleterious and ominous consequence of, normal aging, repetitive subclinical tissue injury or severe persistent tissue injury. Fibrosis is increasingly seen as the next broad-ranging target for therapeutics after Cancer, and there is now a rush to first-in-class therapeutics. The primary cell that lays down fibrotic tissue is the myofibroblast. Until very recently, the biology of myofibroblasts is relatively undeveloped due to a lack of definitive markers, and lack of clear ontogeny. This meeting: 1) Brings together biotech, pharma and academia in a seamless meeting. 2) Focuses on fibrosis as an abnormal wound healing or tissue repair response identifying aberrant developmental pathways, and progenitor cell responses. c) Has a broad focus on basic biology of myofibroblasts, their progenitors, progenitor ontogeny, and their interaction with the immune system in disease. d) Focuses on fibrosis as a normal part of aging and the epigenetics involved in maintaining myofibroblasts in an activated state. e) Includes a full session on biomarkers; among the major blocks to progress is the lack of biomarkers. f) Feature formal presentations from biotech/pharma on the most promising new therapeutics in development or clinical trial. All of these highlighted areas are underdeveloped and are rapidly changing. The Keystone Symposia Fibrosis meeting is intended to be the premier international meeting for anyone with an interest in this disease process. The meeting brings together academics from a broad range of interest areas, including cancer, vascular biology, stem cell biology and tissue regeneration, as well as those with organ specific-interests.
View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference
SUNDAY, MARCH 23
MONDAY, MARCH 24
TUESDAY, MARCH 25
WEDNESDAY, MARCH 26
THURSDAY, MARCH 27
FRIDAY, MARCH 28
Conference Program Print | View meeting in 24 hr (international) time
SUNDAY, MARCH 23
8:15—9:15 AM
Keynote Address
*
Steven R. Ledbetter,
Genzyme Corporation, USA
Harry (Hal) C. Dietz,
Johns Hopkins University School of Medicine, Blade Therapeutics, USA
Insights Regarding the Pathogenesis and Treatment of Scleroderma
Insights Regarding the Pathogenesis and Treatment of Scleroderma
9:15 AM—12:00 PM
Senescence, Cell Stress and the Fibrogenic Response
*
Steven R. Ledbetter,
Genzyme Corporation, USA
*
Erwin P. Böttinger,
Hasso-Plattner-Institut für Digital Engineering GmbH, Germany
Judith Campisi,
Buck Institute for Research on Aging, USA
The Role of Cellular Senescence in Inflammation and Fibrosis
The Role of Cellular Senescence in Inflammation and Fibrosis
Dean Sheppard,
University of California, San Francisco, USA
Fibroblast alphav Integrins as Therapeutic Targets in Tissue Fibrosis
Fibroblast alphav Integrins as Therapeutic Targets in Tissue Fibrosis
John P. Iredale,
University of Bristol, UK
Macrophages and Resolution of Liver Fibrosis
Macrophages and Resolution of Liver Fibrosis
David Lagares,
Massachusetts General Hospital, USA
Short Talk: “Fibronucleation” and Stiffness Gradients Drive Tissue Fibrosis by Promoting Fibroblast Recruitment and Activation through Cell “Durotaxis”
Short Talk: “Fibronucleation” and Stiffness Gradients Drive Tissue Fibrosis by Promoting Fibroblast Recruitment and Activation through Cell “Durotaxis”
Massimiliano Mellone,
University of Southampton, UK
Short Talk: Fibroblast to Myofibroblast Differentiation in Fibrosis and Tumor Microenvironment: Role of DNA Damage Response (DDR) Pathway
Short Talk: Fibroblast to Myofibroblast Differentiation in Fibrosis and Tumor Microenvironment: Role of DNA Damage Response (DDR) Pathway
Neetu Razdan,
Rutgers University, USA
Short Talk: Telomere Dysfunction Is a Mediator of Myofibroblast Transdifferentiation
Short Talk: Telomere Dysfunction Is a Mediator of Myofibroblast Transdifferentiation
5:00—7:15 PM
Metabolic Pathways in Fibrogenesis
*
Thomas A. Wynn,
Pfizer, USA
*
John Varga,
Feinberg School of Medicine, USA
Rik Derynck,
University of California, San Francisco, USA
Control of Epithelial-Mesenchymal Transition by TGF-beta Receptor Presentation
Control of Epithelial-Mesenchymal Transition by TGF-beta Receptor Presentation
Erwin P. Böttinger,
Hasso-Plattner-Institut für Digital Engineering GmbH, Germany
Mitochondrial Dysfunction and Renal Fibrogenesis
Mitochondrial Dysfunction and Renal Fibrogenesis
Nelson Chau,
LogicBio Therapeutics, USA
Oligonucleotide-Mediated Antagonism of Dysregulated MicroRNAs Represents a Novel Therapeutic Strategy for Treatment of Fibrosis
Oligonucleotide-Mediated Antagonism of Dysregulated MicroRNAs Represents a Novel Therapeutic Strategy for Treatment of Fibrosis
Benjamin Korman,
Northwestern University, USA
Short Talk: Adipocyte-Specific Ablation of PPAR-gamma Co-Repressor NCoR Modulates Metabolism and Attenuates Experimental Skin Fibrosis
Short Talk: Adipocyte-Specific Ablation of PPAR-gamma Co-Repressor NCoR Modulates Metabolism and Attenuates Experimental Skin Fibrosis
Monique Bernard,
University of Montreal Hospital Centre - Research Centre, CRCHUM, Canada
Short Talk: mTORC2 Links Autophagy and Myofibroblast Differentiation
Short Talk: mTORC2 Links Autophagy and Myofibroblast Differentiation
7:30—10:00 PM
Poster Session 1:
1A Fate Mapping Studies
1B Metabolic/Stress/Senescence Pathways
1C Scleroderma/Systemic Sclerosis
1D New Insights from Screens
1E Reprogramming/Epigenetics
1F MicroRNA
1G Perivasculature
1A Fate Mapping Studies
1B Metabolic/Stress/Senescence Pathways
1C Scleroderma/Systemic Sclerosis
1D New Insights from Screens
1E Reprogramming/Epigenetics
1F MicroRNA
1G Perivasculature
*
David A. Brenner,
University of California, San Diego, USA
*
Jelena Mann,
Newcastle University, UK
*
Boris Hinz,
University of Toronto, Canada
8:00—11:45 AM
Perivascular and Other Mesenchymal Lineages - Bipolar Cells in Disease and Fibrogenesis
*
Andrew M. Tager,
Massachusetts General Hospital, USA
Jeremy S. Duffield,
Vertex Pharmaceuticals, USA
Mechanisms of Perivascular Cell Activation in Disease
Mechanisms of Perivascular Cell Activation in Disease
Lucie Peduto,
Institut Pasteur, France
The Fate and Function of ADAM12(+) Perivascular Cells in Injury and Fibrosis
The Fate and Function of ADAM12(+) Perivascular Cells in Injury and Fibrosis
Christian Göritz,
Karolinska Institutet, Sweden
The Role of Pericytes in Central Nervous System Scarring and Fibrosis
The Role of Pericytes in Central Nervous System Scarring and Fibrosis
Jonathan M. Graff,
University of Texas Southwestern Medical Center, USA
Adipose Stem Cells: Give me a Pill and not a Treadmill
Adipose Stem Cells: Give me a Pill and not a Treadmill
Ingmar Mederacke,
Columbia University, USA
Short Talk: Fate Tracing Reveals Hepatic Stellate Cells as Main Contributors to the Myofibroblast Pool in Toxic, Biliary and Fatty Liver Disease
Short Talk: Fate Tracing Reveals Hepatic Stellate Cells as Main Contributors to the Myofibroblast Pool in Toxic, Biliary and Fatty Liver Disease
Tien Peng,
University of Pennsylvania, USA
Short Talk: Hedgehog Regulates Fibroblast Proliferation during Normal Tissue Homeostasis and Fibrotic Repair
Short Talk: Hedgehog Regulates Fibroblast Proliferation during Normal Tissue Homeostasis and Fibrotic Repair
*
Andrew Leask,
University of Saskatoon, Canada
Short Talk: Skin Progenitor Cells Contribute to Bleomycin-Induced Skin Fibrosis
Short Talk: Skin Progenitor Cells Contribute to Bleomycin-Induced Skin Fibrosis
2:30—4:30 PM
Workshop 1A: Targeting Matrix Turnover: A Good or a Bad Idea?
*
Heather A. Arnett,
NuMedii, Inc., USA
*
Kamran Atabai,
University of California, San Francisco, USA
Martin L. Decaris,
Pliant Therapeutics, USA
Proteomic Quantitation of Altered Extracellular Matrix Protein Turnover in Animal Models of Pulmonary Fibrosis
Proteomic Quantitation of Altered Extracellular Matrix Protein Turnover in Animal Models of Pulmonary Fibrosis
Terrie-Anne Cock,
Pharmaxis, Australia
Inhibition of TGF-beta Signaling and LOXL2: Pharmaxis’ Dual Small Molecule Approach to Treat Fibrosis
Inhibition of TGF-beta Signaling and LOXL2: Pharmaxis’ Dual Small Molecule Approach to Treat Fibrosis
Ming-Hui Fan,
University of Pittsburgh, USA
Fibroblast Activation Protein (FAP), An Endogenous Regulator of Fibrosis, Participates in Collagen Catabolism
Fibroblast Activation Protein (FAP), An Endogenous Regulator of Fibrosis, Participates in Collagen Catabolism
Thomas H. Barker,
Georgia Institute of Technology, USA
A CD90/Fyn/alphavbeta3 Integrin Mechanosignaling Axis Modulates ECM Rigidity Sensing in Lung Fibrosis
A CD90/Fyn/alphavbeta3 Integrin Mechanosignaling Axis Modulates ECM Rigidity Sensing in Lung Fibrosis
Franco Klingberg,
University of Toronto, Canada
Organized Is More Efficient: Pre-Stress in the ECM Enhances Activation of Latent TGF-beta1 by Myofibroblast Contraction
Organized Is More Efficient: Pre-Stress in the ECM Enhances Activation of Latent TGF-beta1 by Myofibroblast Contraction
Peter D. Mariner,
University of Colorado, USA
Dynamic Hydrogel Platform for Studying the Effects of Environmental Stiffness on Myofibroblast Activation
Dynamic Hydrogel Platform for Studying the Effects of Environmental Stiffness on Myofibroblast Activation
Nathan Sandbo,
University of Wisconsin, USA
Myofibroblasts Exhibit Elevated Fibronectin Assembly that Is Intrinsic to its Contractile Phenotype
Myofibroblasts Exhibit Elevated Fibronectin Assembly that Is Intrinsic to its Contractile Phenotype
2:30—4:30 PM
Workshop 1B: How Best to Regulate Myofibroblast Activation
*
Harry (Hal) C. Dietz,
Johns Hopkins University School of Medicine, Blade Therapeutics, USA
*
Tatiana Kisseleva,
University of California, San Diego, USA
Sergei P. Atamas,
University of Maryland School of Medicine, USA
Deciphering Mechanisms of IL-33-Driven Fibrosis
Deciphering Mechanisms of IL-33-Driven Fibrosis
Christian Beyer,
University of Erlangen-Nuremberg, Germany
The Soluble Guanylate Cyclase (sGC) Inhibits Fibrosis by Interfering with Non-Canonical TGFbeta-Signaling
The Soluble Guanylate Cyclase (sGC) Inhibits Fibrosis by Interfering with Non-Canonical TGFbeta-Signaling
Michael P. Czubryt,
University of Manitoba, Canada
Regulation of Myocardial Fibrogenesis and Fibroblast Phenotype by Scleraxis
Regulation of Myocardial Fibrogenesis and Fibroblast Phenotype by Scleraxis
Emily Hamburg,
Case Western Reserve University, USA
Cell Autonomous Mechanisms of Fibrosis Due to Elevated beta-Catenin Activity in Dermal Fibroblasts
Cell Autonomous Mechanisms of Fibrosis Due to Elevated beta-Catenin Activity in Dermal Fibroblasts
Alison E. John,
University of Nottingham, UK
Alveolar TGF-beta Activation and Lung Homeostasis Is Regulated by Epithelial Gq/G11 Signaling
Alveolar TGF-beta Activation and Lung Homeostasis Is Regulated by Epithelial Gq/G11 Signaling
Katherine M. Martin,
University of Manchester, UK
Integrin Beta1 Regulates Hepatic Stellate Cell Activation
Integrin Beta1 Regulates Hepatic Stellate Cell Activation
Saimir Luli,
Newcastle University, UK
A Novel Liposomal Technology to Selectively Target Hepatic Myofibroblasts
A Novel Liposomal Technology to Selectively Target Hepatic Myofibroblasts
5:00—7:15 PM
Innate and Adaptive Pathways in Fibrogenesis
*
John P. Iredale,
University of Bristol, UK
*
Timothy Radstake,
University Medical Center Utrecht, Netherlands
Paul Kubes,
University of Calgary, Canada
Intravascular Immunity in the Development and Resolution of Sterile Injury
Intravascular Immunity in the Development and Resolution of Sterile Injury
Scott L. Friedman,
Icahn School of Medicine at Mount Sinai, USA
Autophagy Fuels Mesenchymal Cell Fibrogenesis in Liver and Other Tissues
Autophagy Fuels Mesenchymal Cell Fibrogenesis in Liver and Other Tissues
Brigid M. O'Flaherty,
Emory University, USA
Short Talk: Evaluating the Role of MHV68 M1 Induced Vbeta4+CD8+ T Cell Expansion in Development of Pulmonary Fibrosis
Short Talk: Evaluating the Role of MHV68 M1 Induced Vbeta4+CD8+ T Cell Expansion in Development of Pulmonary Fibrosis
Christian Stockmann,
University of Zurich, Switzerland
Short Talk: Sinusoidal Remodeling by Myeloid Cell-Derived VEGF Is Required for the Resolution of Liver Fibrosis
Short Talk: Sinusoidal Remodeling by Myeloid Cell-Derived VEGF Is Required for the Resolution of Liver Fibrosis
7:30—10:00 PM
Poster Session 2:
2A Infectious Mechanisms
2B New Targets
2C Innate/Adaptive Immunity
2D Underrepresented Organs/Diseases
2E Repair/Regeneration
2A Infectious Mechanisms
2B New Targets
2C Innate/Adaptive Immunity
2D Underrepresented Organs/Diseases
2E Repair/Regeneration
*
Lynn M. Schnapp,
University of Wisconsin-Madison, USA
*
Paul Kubes,
University of Calgary, Canada
*
Paul W. Noble,
Cedars-Sinai Medical Center, USA
8:00—11:45 AM
Established and Promising Therapies Entering Clinical Development
*
Dean Sheppard,
University of California, San Francisco, USA
*
Mark L. Lupher, Jr.,
Muregen, LLC, USA
Paul W. Noble,
Cedars-Sinai Medical Center, USA
Update on Clinical Trials in Idiopathic Pulmonary Fibrosis
Update on Clinical Trials in Idiopathic Pulmonary Fibrosis
Naftali Kaminski,
Yale University School of Medicine, USA
MicroRNAs in Lung Fibrosis
MicroRNAs in Lung Fibrosis
Elizabeth G. Trehu,
Jounce Therapeutics, USA
and
and
Bernt van den Blink,
Erasmus MC, Netherlands
PRM-151 in Idiopathic Pulmonary Fibrosis and Myelofibrosis
PRM-151 in Idiopathic Pulmonary Fibrosis and Myelofibrosis
Andrew M. Tager,
Massachusetts General Hospital, USA
Lysophosphatidic Acid (LPA)-LPA1 Signaling in Fibrogenesis
Lysophosphatidic Acid (LPA)-LPA1 Signaling in Fibrogenesis
Jeffrey R. Crosby,
Ionis Pharmaceuticals, Inc., USA
Short Talk: Inhaled Antisense Oligonucleotides for the Treatment of Pulmonary Fibrosis: The Role of Osteopontin in Mouse Models of Disease
Short Talk: Inhaled Antisense Oligonucleotides for the Treatment of Pulmonary Fibrosis: The Role of Osteopontin in Mouse Models of Disease
Cédric Szyndralewiez,
Genkyotex, Switzerland
Short Talk: The NADPH Oxidase (NOX) Inhibitor GKT137831 Alleviates Liver Inflammation and Fibrosis in a Mouse Model of Non-Alcoholic Steatohepatitis (NASH)
Short Talk: The NADPH Oxidase (NOX) Inhibitor GKT137831 Alleviates Liver Inflammation and Fibrosis in a Mouse Model of Non-Alcoholic Steatohepatitis (NASH)
Timothy Radstake,
University Medical Center Utrecht, Netherlands
Short Talk: The Chemokine CXCL4 Is a Novel biomarker in Systemic Sclerosis Linking Inflammation, Endothelial Dysfunction and Fibrosis
Short Talk: The Chemokine CXCL4 Is a Novel biomarker in Systemic Sclerosis Linking Inflammation, Endothelial Dysfunction and Fibrosis
Mushriq Al-Jazrawe,
University of Toronto, Canada
Short Talk: Preventing Fibrosis by Targeting beta-Catenin: A Preclinical Study of Topical Nefopam
Short Talk: Preventing Fibrosis by Targeting beta-Catenin: A Preclinical Study of Topical Nefopam
5:00—7:15 PM
Promising New Pathways in Fibrogenesis
*
Paul W. Noble,
Cedars-Sinai Medical Center, USA
*
Victoria Smith,
Gilead Sciences, USA
Heather A. Arnett,
NuMedii, Inc., USA
Identifying Novel Myofibroblast Pathways in IPF Lungs
Identifying Novel Myofibroblast Pathways in IPF Lungs
Robert Lafyatis,
University of Pittsburgh Medical Center, USA
Anti-TGF-beta/Fresolimumab Inhibition of Skin Fibrosis and TGF-beta-Regulated Biomarker Gene Expression in Patients with Systemic Sclerosis
Anti-TGF-beta/Fresolimumab Inhibition of Skin Fibrosis and TGF-beta-Regulated Biomarker Gene Expression in Patients with Systemic Sclerosis
Greg R. Dressler,
University of Michigan, USA
Novel TGF-beta Superfamily Regulators in Renal Fibrosis
Novel TGF-beta Superfamily Regulators in Renal Fibrosis
James P. Pritchett,
University of Manchester, UK
Short Talk: A Role for Mechano-Transduction via Yap/Taz in Hepatic Stellate Cell Activation
Short Talk: A Role for Mechano-Transduction via Yap/Taz in Hepatic Stellate Cell Activation
Cristi L. Galindo,
Vanderbilt University, USA
Short Talk: Neuregulin Inhibits Cardiac Fibrosis and Mediates Anti-Fibrotic Signaling in Cardiac Fibroblasts
Short Talk: Neuregulin Inhibits Cardiac Fibrosis and Mediates Anti-Fibrotic Signaling in Cardiac Fibroblasts
7:30—10:00 PM
Poster Session 3:
3A Clinical Trials
3B Biomarkers/Monitoring/Devices
3C New Models
3D Signaling
3E Matrix Signaling to Cells
3A Clinical Trials
3B Biomarkers/Monitoring/Devices
3C New Models
3D Signaling
3E Matrix Signaling to Cells
*
Bruno Péault,
University of California, Los Angeles, USA
*
Stuart J. Forbes,
University of Edinburgh, UK
*
Andrew M. Tager,
Massachusetts General Hospital, USA
8:00—11:45 AM
Resolution of Fibrosis and Pathways of Repair and Regeneration
*
Jeremy S. Duffield,
Vertex Pharmaceuticals, USA
*
Tien Peng,
University of Pennsylvania, USA
Bruno Péault,
University of California, Los Angeles, USA
Role of Vascular Pericytes in Normal and Pathologic Tissue Regeneration
Role of Vascular Pericytes in Normal and Pathologic Tissue Regeneration
Gabrielle Kardon,
University of Utah, USA
Interactions between Muscle Stem Cells, Fibroblasts and Macrophages Are Critical for Muscle Regeneration
Interactions between Muscle Stem Cells, Fibroblasts and Macrophages Are Critical for Muscle Regeneration
Stuart J. Forbes,
University of Edinburgh, UK
Liver Regeneration
Liver Regeneration
Michelle D. Tallquist,
University of Hawaii, USA
Cardiac Resident Mesenchymal Cells in Organogensis and Fibrosis
Cardiac Resident Mesenchymal Cells in Organogensis and Fibrosis
Dario R. Lemos,
University of British Columbia, Canada
Short Talk: The Innate Immune Response Modulates Fibrosis during Skeletal Muscle Regeneration via TNF-alpha/TGF-beta Signaling on Mesenchymal Multipotent Cells
Short Talk: The Innate Immune Response Modulates Fibrosis during Skeletal Muscle Regeneration via TNF-alpha/TGF-beta Signaling on Mesenchymal Multipotent Cells
Laura Johnson,
University of Michigan, USA
Short Talk: Intestinal Organoids: A Model of Intestinal Fibrosis
Short Talk: Intestinal Organoids: A Model of Intestinal Fibrosis
Wilder Scott,
University of British Columbia, Canada
Short Talk: Analysis of Mesenchymal Stromal Cell Fate in Tissue Regeneration
Short Talk: Analysis of Mesenchymal Stromal Cell Fate in Tissue Regeneration
Norihiko Takeda,
University of Tokyo, Japan
Short Talk: Roles of Macrophages Hypoxia Signaling in Cardiac Fibrosis
Short Talk: Roles of Macrophages Hypoxia Signaling in Cardiac Fibrosis
2:30—4:30 PM
Workshop 2A: Non-Invasive Monitoring of Fibrosis, Biomarkers and Devices
*
Scott L. Friedman,
Icahn School of Medicine at Mount Sinai, USA
Edford Sinkala,
University Teaching Hospital, Zambia
High Concentration of Fibrotic and Inflammatory Markers among Patients with Schistosomal Liver Diseases
High Concentration of Fibrotic and Inflammatory Markers among Patients with Schistosomal Liver Diseases
Scott M. Turner,
Pliant Therapeutics, USA
Identification of a Putative Serum Protein Biomarker for Noninvasive Measurement of Fibrogenesis: Correlation with Hepatic Collagen Synthesis and Histological Score in Humans
Identification of a Putative Serum Protein Biomarker for Noninvasive Measurement of Fibrogenesis: Correlation with Hepatic Collagen Synthesis and Histological Score in Humans
John A. Baugh,
University College Dublin, Ireland
Serum Amyloid P-Component: A Novel Biomarker and Potential Treatment for Left Ventricular Remodelling and Heart Failure
Serum Amyloid P-Component: A Novel Biomarker and Potential Treatment for Left Ventricular Remodelling and Heart Failure
Thomas H. Barker,
Georgia Institute of Technology, USA
A New Modality for Imaging Fibrosis - Detection of an Extracellular Integrin “Switch” A Conformation Specific Antibody against Fibronectin for Imaging of Fibrosis
A New Modality for Imaging Fibrosis - Detection of an Extracellular Integrin “Switch” A Conformation Specific Antibody against Fibronectin for Imaging of Fibrosis
Florin L. Craciun,
Brigham & Women's Hospital/ Harvard Medical School, USA
Discovery of 12 New Candidate Biomarkers for Chronic Kidney Disease: From Mouse Models to Human Patients
Discovery of 12 New Candidate Biomarkers for Chronic Kidney Disease: From Mouse Models to Human Patients
Claire Emson,
Genentech, Inc., USA
Collagen Synthesis Rate Distinguishes between Early and Late Diffuse Scleroderma Subjects
Collagen Synthesis Rate Distinguishes between Early and Late Diffuse Scleroderma Subjects
Jose D. Herazo-Maya,
Yale University, USA
A 52 Peripheral Blood Gene Signature Predicts Poor Outcome and Disease Progression in Idiopathic Pulmonary Fibrosis
A 52 Peripheral Blood Gene Signature Predicts Poor Outcome and Disease Progression in Idiopathic Pulmonary Fibrosis
Mette Juul Nielsen,
Nordic Bioscience, Denmark
Serological Markers of Extracellular Matrix Remodeling Enables Early Diagnosis and Predicts Fibrosis Progression of Chronic Hepatitis C
Serological Markers of Extracellular Matrix Remodeling Enables Early Diagnosis and Predicts Fibrosis Progression of Chronic Hepatitis C
Karl Kossen,
Blade Therapeutics, USA
Plasma MMP-7 Predicts Mortality in Idiopathic Pulmonary Fibrosis
Plasma MMP-7 Predicts Mortality in Idiopathic Pulmonary Fibrosis
2:30—4:30 PM
Workshop 2B: New Pathways/Drugs from SCREENS
*
Linda C. Burkly,
Biogen, Inc., USA
*
Stuart J. Forbes,
University of Edinburgh, UK
David Zhang,
Mount Sinai School of Medicine, USA
A Genomics Strategy Highlights Hand2 Regulation in Hepatic Stellate Cell Activation
A Genomics Strategy Highlights Hand2 Regulation in Hepatic Stellate Cell Activation
Kamran Atabai,
University of California, San Francisco, USA
Functional Genomic Screen Identifies Novel Mediators of Collagen Uptake and Turnover
Functional Genomic Screen Identifies Novel Mediators of Collagen Uptake and Turnover
Xavier Espanel,
NovAliX Belgique, France
Development and Automation of a Fibrotic Phenotypic Screening Using a High Content Screening Approach
Development and Automation of a Fibrotic Phenotypic Screening Using a High Content Screening Approach
David W. Griggs,
St. Louis University, USA
Preclinical Development of Multi-Functional Integrin Antagonists for Treatment of Organ Fibrosis
Preclinical Development of Multi-Functional Integrin Antagonists for Treatment of Organ Fibrosis
John B. Nicholas,
InterMune, Inc., USA
Phenotypic Screening for Inhibitors of Fibroblast to Myofibroblast Transition (FMT)
Phenotypic Screening for Inhibitors of Fibroblast to Myofibroblast Transition (FMT)
Kevin K. Kim,
University of Michigan, USA
Overexpression of Id2 Transcription Factor Promotes Alveolar Epithelial Cell Proliferation and Attenuates Belomycin-Induced Pulmonary Fibrosis
Overexpression of Id2 Transcription Factor Promotes Alveolar Epithelial Cell Proliferation and Attenuates Belomycin-Induced Pulmonary Fibrosis
Branko Stefanovic,
Florida State University, USA
Discovery and Validation of a Potent Antifibrotic Drug with Unique Mechanism of Action
Discovery and Validation of a Potent Antifibrotic Drug with Unique Mechanism of Action
5:00—7:00 PM
Myofibroblast Reprogramming
*
Naftali Kaminski,
Yale University School of Medicine, USA
*
Michelle D. Tallquist,
University of Hawaii, USA
David A. Brenner,
University of California, San Diego, USA
Myofibroblast Inactivation in the Resolution of Fibrosis
Myofibroblast Inactivation in the Resolution of Fibrosis
Jelena Mann,
Newcastle University, UK
Epigenetics in Myofibroblast Reprogramming
Epigenetics in Myofibroblast Reprogramming
Boris Hinz,
University of Toronto, Canada
The Effect of the Mechanical Environment on Myofibroblast Development and Persistence
The Effect of the Mechanical Environment on Myofibroblast Development and Persistence
Eleni Stylianou,
Lerner Research Institute, Cleveland Clinic, USA
Short Talk: Defining the Fibrotic DNA Methylome in Crohn’s Disease
Short Talk: Defining the Fibrotic DNA Methylome in Crohn’s Disease
*Session Chair †Invited, not yet responded.
We gratefully acknowledge support for this conference from:
Keystone Symposia thanks our Sponsors(s) for generously supporting this meeting:
|
|
|
|
|
|
We gratefully acknowledge additional support for this conference from:
|
|
|
|
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:
Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:
Click here to view more of these organizations
|
If your organization is interested in joining these entities in support of Keystone
Symposia, please contact: Sarah Lavicka,
Director of Corporate Relations, Email: sarahl@keystonesymposia.org, Phone:+1 970-262-2690 Click here for more information on Industry Support and Recognition Opportunities. If you are interested in becoming an advertising/marketing in-kind partner, please contact: Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org, Phone:+1 970-262-1179 |
